Katharina Endres
Overview
Explore the profile of Katharina Endres including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
17
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kuzin M, Haen E, Kuzo N, Endres K, Hiemke C, Paulzen M, et al.
Ther Drug Monit
. 2024 Feb;
46(2):246-251.
PMID: 38377253
Background: To assess the pharmacokinetic correlates of reported adverse drug reactions (ADRs) under antidepressant treatment with escitalopram (ESC) using a large therapeutic drug monitoring database. Methods: A large naturalistic sample...
2.
Gaebler A, Haen E, Omar N, Endres K, Hiemke C, Schoretsanitis G, et al.
Pharmacol Res Perspect
. 2023 Feb;
11(2):e01065.
PMID: 36825450
Augmentation of antipsychotic treatment with antidepressants represents a common and beneficial treatment strategy in patients suffering from schizophrenia. Combining clozapine and the selective serotonin reuptake inhibitor (SSRI) sertraline represents a...
3.
Schoretsanitis G, Haen E, Piacentino D, Conca A, Endres K, Hiemke C, et al.
Expert Rev Clin Pharmacol
. 2021 Dec;
15(2):243-249.
PMID: 34918984
Objectives: Knowledge about the impact of body composition features on pharmacokinetics of newer long-acting injectable antipsychotics is limited. Methods: We analyzed steady-state plasma concentrations of paliperidone in different body mass...
4.
Schoretsanitis G, Haen E, Piacentino D, Conca A, Endres K, Carpi F, et al.
Clin Pharmacokinet
. 2021 Jun;
60(12):1583-1589.
PMID: 34142360
Objective: The objective of this study was to investigate associations between pharmacokinetic correlates and once-monthly paliperidone palmitate (PP1M)-related adverse drug reactions (ADRs). Methods: Plasma concentrations and dose-adjusted plasma concentrations ('concentration-by-dose'...
5.
Schoretsanitis G, Haen E, Piacentino D, Conca A, Endres K, Hiemke C, et al.
Eur Arch Psychiatry Clin Neurosci
. 2021 Apr;
271(8):1437-1443.
PMID: 33821323
To investigate pharmacokinetic correlates of clinical response in patients treated with once-monthly paliperidone palmitate (PP1M) injections at steady state. Plasma concentrations and dose-adjusted-plasma concentrations (C/D) of paliperidone from a naturalistic...
6.
Endres K, Schiller E, Haen E
Nervenarzt
. 2020 Sep;
92(5):487-493.
PMID: 32986155
Background: Patients with mental illnesses are at increased risk of cardiovascular disease-related mortality. Antihypertensive drugs are used particularly for the prophylaxis and treatment of cardiovascular diseases. In combination with psychiatric...
7.
Gaebler A, Schoretsanitis G, Omar N, Haen E, Endres K, Hiemke C, et al.
Br J Clin Pharmacol
. 2020 Jul;
87(3):1111-1119.
PMID: 32652557
Aim: Comorbidity of pain and depression or anxiety is a challenging clinical phenomenon, often requiring the concurrent application of antidepressant and analgesic drugs. Growing evidence suggests that the analgesic metamizole...
8.
Kowalewski C, Haen E, Hiemke C, Ridders F, Endres K, Grunder G, et al.
Int Clin Psychopharmacol
. 2019 May;
34(5):241-246.
PMID: 31094902
Objective: The aim of this study was to ensure patients' safety and to enhance treatment efficacy, knowledge about pharmacokinetic interactions even in complex clinical situations of polypharmacy is invaluable. This...
9.
Schoretsanitis G, Haen E, Grunder G, Hiemke C, Endres K, Ridders F, et al.
Eur J Clin Pharmacol
. 2019 Apr;
75(8):1109-1116.
PMID: 30968172
Purpose: To assess in a large naturalistic sample, whether clinical response to a treatment with venlafaxine is associated with different patterns of plasma concentrations of active moiety, AM (sum of...
10.
Schoretsanitis G, Haen E, Hiemke C, Endres K, Ridders F, Veselinovic T, et al.
Eur Arch Psychiatry Clin Neurosci
. 2019 Mar;
269(7):851-857.
PMID: 30923938
To address the potential correlation between plasma concentrations of venlafaxine (VEN), its active metabolite O-desmethylvenlafaxine (ODVEN) and the active moiety, AM, (ODVEN + VEN) and adverse drug reactions (ADR) in...